Sandbox g19: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
Line 4: | Line 4: | ||
:* Brain abscess in otherwise healthy patients | :* Brain abscess in otherwise healthy patients | ||
::* Preferred regimen | ::* Preferred regimen | ||
:::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h {{and}} [[Metronidazole]] 30 mg/kg/day q6h | :::* [[Cefotaxime]] 8–12 g/day IV q4–6h {{or}} [[Ceftriaxone]] 4 g/day IV q12h {{and}} [[Metronidazole]] 30 mg/kg/day IV q6h | ||
::* Alternative regimen | ::* Alternative regimen | ||
:::* [[Meropenem]] 6 g/day q8h | :::* [[Meropenem]] 6 g/day IV q8h | ||
:* Brain abscess with comorbidities | :* Brain abscess with comorbidities |
Revision as of 05:02, 5 June 2015
Brain abscess
- Empiric antimicrobial therapy
- Brain abscess in otherwise healthy patients
- Preferred regimen
- Cefotaxime 8–12 g/day IV q4–6h OR Ceftriaxone 4 g/day IV q12h AND Metronidazole 30 mg/kg/day IV q6h
- Alternative regimen
- Meropenem 6 g/day IV q8h
- Brain abscess with comorbidities